Last updated: August 31, 2026
Seasonale is a mature extended-cycle oral contraceptive containing levonorgestrel and ethinyl estradiol. Its commercial value has shifted from branded-product growth to low-cost generic volume. Teva Pharmaceuticals inherited the product through its acquisition of Barr Pharmaceuticals, but Teva does not report Seasonale revenue separately. The product has no meaningful remaining regulatory exclusivity, and its patent position is unlikely to prevent generic substitution.
What is Seasonale and how does it work?
Seasonale is a 91-day combined oral contraceptive regimen containing:
| Product characteristic |
Seasonale specification |
| Active ingredients |
Levonorgestrel 0.15 mg and ethinyl estradiol 0.03 mg |
| Dosage form |
Oral tablets |
| Regimen |
84 consecutive active tablets followed by 7 inactive tablets |
| Expected withdrawal bleeding |
Approximately four episodes annually |
| Original U.S. applicant |
Barr Laboratories |
| FDA approval |
September 2003 |
| U.S. NDA |
NDA 021543 |
| Therapeutic category |
Hormonal contraception |
Seasonale reduced the number of scheduled withdrawal bleeds compared with conventional 28-day oral contraceptives. Its clinical and commercial differentiation was based primarily on dosing frequency rather than a new molecular entity or novel delivery system (U.S. Food and Drug Administration [FDA], 2003).
The active ingredients are established generic hormones. The principal commercial variables are brand recognition, formulary placement, retail price, adherence, packaging and physician familiarity.
What is the FDA regulatory status of Seasonale?
Seasonale was approved through the conventional new drug application pathway and is not a biologic. It does not have biosimilar exposure because biosimilar law applies to biologic products, not small-molecule oral contraceptives.
The FDA-approved product has historically been marketed under the Seasonale brand and through generic equivalents containing the same active ingredients and extended-cycle regimen. Regulatory exclusivity associated with the original approval has expired. No current orphan-drug, pediatric, new chemical entity or other exclusivity is expected to block generic competition.
FDA regulatory milestones
| Date |
Event |
| September 2003 |
FDA approval of Seasonale under NDA 021543 |
| 2000s |
Expansion of extended-cycle contraceptive competition, including Seasonique and other regimens |
| Late 2000s onward |
Generic levonorgestrel/ethinyl estradiol extended-cycle products enter the U.S. market |
| 2010s-2020s |
Product becomes a mature, genericized oral contraceptive category |
| July 2023 |
FDA approves Opill, the first U.S. nonprescription daily oral contraceptive, expanding consumer access to hormonal contraception but not directly replacing Seasonale’s combined-hormone regimen |
The FDA’s Orange Book identifies approved products and, where applicable, listed patents and exclusivity. Seasonale’s commercial position is no longer supported by an active regulatory exclusivity period comparable to the protection available to a newly approved product (FDA, n.d.-a).
What patents protect Seasonale?
Seasonale’s original intellectual-property strategy centered on the extended-cycle contraceptive regimen rather than on proprietary active ingredients. Levonorgestrel and ethinyl estradiol were long-established compounds before Seasonale’s approval.
The relevant protection categories were:
- Patents covering extended-cycle administration of oral contraceptives.
- Patents covering packaging and dosing schedules.
- Potential method-of-use claims directed to reducing the frequency of withdrawal bleeding.
- Trademark protection for the Seasonale brand.
The main patent estate was time-limited and did not create a durable barrier against generic products. Patent protection for the underlying active ingredients was already expired. Any regimen patents associated with the original product would have reached their ordinary expiration dates years ago, subject to patent-term adjustment and any applicable regulatory extensions.
What is the Orange Book status of Seasonale?
The Orange Book is the primary source for current FDA-listed patents and generic-substitution information. Seasonale is a small-molecule product with an approved NDA and generic competition. The practical Orange Book implication is that an abbreviated new drug application can rely on the reference product’s safety and efficacy findings, subject to the applicable patent certifications and FDA requirements.
There is no commercial indication that an unexpired Seasonale patent currently prevents generic substitution. The brand’s remaining differentiation is commercial rather than patent-based.
When did Seasonale lose exclusivity?
Seasonale lost meaningful market exclusivity after the entry of generic extended-cycle levonorgestrel/ethinyl estradiol products. The exact first commercial generic launch date can differ from the date of FDA approval because approval, Paragraph IV litigation, settlement terms and commercial launch timing are separate events.
The economic sequence was:
| Stage |
Market effect |
| 2003 approval |
Brand established a new extended-cycle contraceptive segment |
| Initial post-launch period |
Seasonale captured premium pricing and physician attention |
| Generic approvals |
Payers gained lower-cost substitution options |
| Generic commercialization |
Pharmacy-level substitution reduced branded volume |
| Mature category |
Price, formulary access and supply reliability became more important than patent protection |
Seasonale therefore moved from an innovation-led product to a maintenance brand. Its commercial life resembles other mature oral contraceptives in which the active ingredient combination is widely available and the brand retains only limited pricing power.
How strong is the Seasonale patent estate?
Seasonale’s current patent estate is weak from a market-exclusion perspective.
| Patent-estate factor |
Assessment |
| Novel active ingredient |
None |
| New chemical entity protection |
None |
| Biologic exclusivity |
Not applicable |
| Current regulatory exclusivity |
Expired |
| Formulation complexity |
Low |
| Manufacturing complexity |
Low to moderate |
| Generic substitution risk |
High |
| Brand pricing power |
Low |
| Device or delivery-system protection |
None of material commercial significance |
| Litigation leverage |
Limited |
The product uses conventional oral tablets and established manufacturing technology. A generic manufacturer does not need a specialized device, cold-chain network or complex biologic process. Manufacturing barriers are therefore modest.
The principal technical requirements concern content uniformity, dissolution, stability, packaging and compliance with FDA specifications. These requirements can affect supply quality but do not normally create a durable barrier to entry.
What generic entry risks affect Seasonale?
Generic entry risk is high because the product has all the characteristics that encourage ANDA competition:
- Established active ingredients.
- Conventional oral-tablet formulation.
- Large historical patient population.
- Clear reference-product pathway.
- No biologic comparability burden.
- No meaningful current exclusivity.
- Low switching cost for pharmacists and payers.
- Multiple potential manufacturers.
Generic applicants may use Paragraph III certifications if relevant patents have expired or Paragraph IV certifications if they assert that listed patents are invalid, unenforceable or not infringed. For a mature product such as Seasonale, the commercial issue is no longer whether generics can eventually enter. It is whether generic manufacturers can maintain supply, secure payer contracts and compete on price.
No major current Paragraph IV dispute is central to Seasonale’s commercial valuation. The original patent-related risk was largely resolved through patent expiration and genericization rather than through a continuing branded litigation campaign.
Which companies compete with Seasonale?
Seasonale competes across three groups: generic manufacturers, branded extended-cycle contraceptives and alternative contraceptive methods.
Generic oral contraceptives
Generic levonorgestrel/ethinyl estradiol extended-cycle products are the closest substitutes. Generic manufacturers typically compete through:
- Wholesale acquisition price.
- Pharmacy benefit manager contracts.
- Retail pharmacy availability.
- Supply continuity.
- Authorized-generic arrangements.
- State Medicaid and public-program access.
The brand’s ability to maintain a premium depends on whether patients or prescribers specifically request Seasonale and whether payers impose generic-first rules.
Branded extended-cycle products
Seasonale has faced branded competition from products such as:
- Seasonique, an extended-cycle regimen with low-dose ethinyl estradiol tablets during the hormone-free interval.
- LoSeasonique, a lower-estrogen version of the extended-cycle concept.
- Other extended-cycle and continuous oral contraceptives.
These products compete on bleeding profile, estrogen exposure, packaging, tolerability and prescriber preference. The distinctions can support product segmentation, but they do not eliminate substitution pressure within the broader oral-contraceptive market.
Non-oral contraception
Seasonale also competes indirectly with:
- Long-acting reversible contraceptives.
- Transdermal patches.
- Vaginal rings.
- Progestin-only pills.
- Injectable contraception.
- Over-the-counter Opill.
Long-acting methods can reduce daily adherence requirements. Opill expands access to a progestin-only pill but does not provide a direct clinical substitute for Seasonale, which is a combined estrogen-progestin product.
What is Seasonale’s financial trajectory?
Seasonale’s standalone revenue is not publicly disclosed. Teva reports financial results by business segment and product group rather than providing a separate Seasonale revenue line. As a result, product-level sales, gross margin and net contribution cannot be established from public company reporting alone (Teva Pharmaceutical Industries Ltd., 2024).
The financial trajectory is nevertheless clear:
Initial growth phase
Following the 2003 approval, Seasonale benefited from:
- Novel dosing convenience.
- Limited direct competition.
- Brand-level pricing.
- Physician education.
- Consumer interest in fewer scheduled periods.
The product likely generated its highest strategic value during the period before broad generic competition.
Generic erosion phase
After generic alternatives became available, the brand faced:
- Pharmacy substitution.
- Lower reimbursement.
- Formulary exclusion or nonpreferred status.
- Reduced physician incentive to prescribe the brand.
- Lower net price after rebates.
- Greater dependence on patient brand preference.
Revenue erosion in this phase typically occurs faster than prescription erosion because branded net price declines through rebates and discounts before prescription volume fully disappears.
Mature maintenance phase
Seasonale’s current economics are more consistent with a mature portfolio product than a growth asset. Financial value may persist through:
- Residual brand demand.
- Cash-pay consumers.
- Patients with established treatment preferences.
- Channel-specific contracts.
- Portfolio efficiencies in manufacturing and distribution.
The product is unlikely to be a meaningful standalone growth driver for Teva. Its strategic value is more likely tied to portfolio completeness, established demand and low incremental commercial investment.
What revenue exposure does Seasonale create for Teva?
Seasonale’s revenue exposure is limited by generic competition and the absence of separately reported product sales. The product’s financial risk is asymmetric:
| Risk or opportunity |
Financial effect |
| Generic price competition |
Compresses net sales and margin |
| Supply disruption |
Can accelerate switching to other generics |
| Brand loyalty |
Preserves a residual premium segment |
| Payer exclusion |
Reduces reimbursed prescriptions |
| OTC contraceptive expansion |
Increases consumer access but intensifies category competition |
| Manufacturing efficiency |
Can protect contribution margin at lower volume |
| Regulatory changes |
May affect access, labeling or prescribing patterns |
Seasonale should not be valued like a protected branded medicine. Its likely contribution is a small, mature stream of product revenue within a larger women’s-health or generic portfolio.
What litigation and settlement agreements affect Seasonale?
The material legal issues for Seasonale were historically tied to generic entry and the validity or scope of regimen-related patent claims. Current public information does not indicate a major active litigation campaign that materially changes the product’s competitive outlook.
Settlement agreements involving generic entry can affect the precise timing of launch, but they do not restore long-term exclusivity after the underlying patents expire. In a mature product category, any settlement-related launch restriction would have diminishing financial significance unless it delayed multiple generic competitors simultaneously.
Trademark enforcement can protect the Seasonale name and packaging. It does not prevent sale of therapeutically equivalent generic products.
How does Seasonale compare with newer contraceptive products?
| Factor |
Seasonale |
Newer branded contraceptive |
Long-acting contraceptive |
| Active ingredient novelty |
Low |
Variable |
Variable |
| Dosing frequency |
Quarterly withdrawal bleeding |
Product-specific |
Months to years |
| Generic substitution |
High |
Variable |
Lower for device brands |
| Patent strength |
Weak or expired |
Potentially stronger |
Often device and method patents |
| Manufacturing complexity |
Low |
Low to moderate |
Moderate to high |
| Pricing power |
Low |
Moderate or high before loss of exclusivity |
Often higher |
| Adherence burden |
Daily |
Usually daily or periodic |
Low after administration |
| Main commercial differentiator |
Extended-cycle schedule |
Tolerability, dosing or formulation |
Duration and convenience |
Seasonale remains clinically relevant for patients who prefer fewer scheduled withdrawal bleeds, but its commercial position is weaker than products protected by a novel molecule, proprietary device or complex delivery technology.
What generic launch scenarios exist for Seasonale?
The most likely market scenarios are:
- Continued generic dominance. Generic products retain most payer-covered volume, while Seasonale remains a residual brand.
- Brand contraction. Payers eliminate preferred coverage, reducing the brand to cash-pay and loyalty-driven demand.
- Supply-driven temporary recovery. Generic shortages may produce short-term brand demand, but the effect would likely be reversible.
- Portfolio rationalization. The marketer may reduce promotional spending or discontinue the branded presentation if net sales no longer justify distribution costs.
- Stable niche demand. The brand persists where patients, prescribers or plans value continuity despite generic availability.
The base case is continued low-growth or declining branded revenue, with generic manufacturers capturing the majority of prescription volume.
Key Takeaways
- Seasonale is a mature extended-cycle combined oral contraceptive approved by the FDA in 2003.
- Its active ingredients are levonorgestrel and ethinyl estradiol.
- Regulatory exclusivity and meaningful patent-based market protection have expired.
- Generic substitution risk is high because the formulation uses established hormones and conventional tablets.
- Teva does not disclose Seasonale revenue separately, preventing a reliable standalone sales estimate.
- The product’s financial trajectory is one of peak branded value followed by generic erosion and mature maintenance.
- No biosimilar risk applies because Seasonale is a small-molecule drug.
- Manufacturing barriers are modest, and the principal commercial barriers are payer access, supply reliability and brand recognition.
- Seasonale’s current value is likely portfolio-based rather than growth-oriented.
FAQs About Seasonale Market and Patent Risk
Is Seasonale still available in the United States?
Seasonale and therapeutically equivalent generic extended-cycle oral contraceptives have been marketed in the United States, although commercial availability can vary by pharmacy, wholesaler and manufacturer.
Does Seasonale have a generic equivalent?
Yes. Generic products containing levonorgestrel 0.15 mg and ethinyl estradiol 0.03 mg in an extended-cycle regimen are available or have been approved for the Seasonale reference-product pathway.
Is Seasonale covered by insurance?
Coverage depends on the payer, formulary and applicable contraceptive coverage rules. Generic equivalents are generally more likely to receive preferred coverage than the branded product.
Can Seasonale lose market share to Opill?
Opill can compete for some oral-contraceptive users, but it is a progestin-only pill and is not a direct substitute for Seasonale’s combined estrogen-progestin regimen.
Is Seasonale an attractive licensing asset?
Seasonale has limited licensing appeal as a standalone branded asset because its patents and exclusivity have expired. Its value is more likely to arise in a broader women’s-health portfolio, generic franchise or distribution arrangement.
References
-
U.S. Food and Drug Administration. (2003). Seasonale prescribing information and NDA 021543. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2023). FDA approves first nonprescription daily oral contraceptive. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive
-
Teva Pharmaceutical Industries Ltd. (2024). Annual report for the year ended December 31, 2023. https://www.teva.com/investors/financial-information/annual-reports/
